A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

To join this study, you would generally need to have a confirmed diagnosis of a solid tumour. For those with liver cancer (hepatocellular carcinoma, or HCC), you would need to have cancer that cannot be removed by surgery, and your diagnosis should be confirmed by a biopsy or by specific medical guidelines. If you have other types of solid tumours (not HCC), your cancer should be confirmed by a biopsy, and there should be no other standard or effective treatments available for your condition.

There are also some general health requirements. You should typically expect to live for at least 12 more weeks, and your general health and ability to do daily activities should be good (known as an ECOG Performance Status of 0 or 1). Any side effects from previous cancer treatments, like chemotherapy or radiotherapy, should have mostly cleared up – usually down to a very mild level, except for hair loss or some mild nerve problems.

Your blood pressure, kidney function, bone marrow (which makes blood cells), liver function, and levels of minerals in your blood must all be within a healthy range. You would also need to have at least one tumour that can be measured accurately by scans. There are specific waiting periods after any previous cancer treatments (like chemotherapy, radiotherapy, or antibody treatments) before you can start the study drugs.

If you decide to take part in this study, the doctors and nurses will monitor you very closely. You will be given the study drug E7386 in combination with other anti-cancer medications like Lenvatinib, Doxorubicin, or Paclitaxel. The main aim is to find the best and safest dose of these drug combinations. This means that the dose you receive might be adjusted based on how you respond and any side effects you experience.

You will have regular visits to the clinic for medical check-ups, blood tests, and scans to see how the treatment is affecting your cancer and your overall health. These assessments are important to track the treatment's effectiveness and to check for any side effects. The exact number of visits, tests, and the total duration of your participation would be fully explained by the study team. While the dose-escalation and expansion parts have finished, the current part focuses on finding the best dose for endometrial cancer patients, which involves ongoing assessments. You'll be closely followed up to understand the full effects of the treatment.